Thomas L. Force
Impact in
-
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac Fibrosis and Remodeling
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Oncology top 0.5%
- Cancer Treatment and Pharmacology
Papers in
-
- Chemotherapy-induced cardiotoxicity and mitigation 23
- Cardiac Fibrosis and Remodeling 19
- Cardiac electrophysiology and arrhythmias 17
- Cardiovascular Function and Risk Factors 15
-
- Signaling Pathways in Disease 23
- Protein Kinase Regulation and GTPase Signaling 18
- Wnt/β-catenin signaling in development and cancer 14
- Melanoma and MAPK Pathways 14
- Co-authors
- Joseph Vincent Bonventre (25 shared papers)Risto Kerkelä (15 shared papers)John M. Kyriakis (17 shared papers)James Robert Woodgett (16 shared papers)Richard A. Van Etten (2 shared papers)Gerald W. Dorn (1 shared paper)Anthony Rosenzweig (11 shared papers)Roger Hajjar (10 shared papers)
- Journals
- Circulation (20 papers)Journal of Biological Chemistry (17 papers)Circulation Research (15 papers)Molecular and Cellular Biology (9 papers)Journal of the American College of Cardiology (8 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Thomas L. Force
166 papers receiving 20.3k citations
Thomas L. Force's Hit Papers
Peers
Comparison fields: 5 of 162
- Cardiology and Cardiovascular Medicine 8.7k
- Oncology 3.7k
- Molecular Biology 8.8k
- Hematology 941
- Pathology and Forensic Medicine 1.3k
Countries citing papers authored by Thomas L. Force
This map shows the geographic impact of Thomas L. Force's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas L. Force with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas L. Force more than expected).
Fields of papers citing papers by Thomas L. Force
This network shows the impact of papers produced by Thomas L. Force. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas L. Force. The network helps show where Thomas L. Force may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas L. Force, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 168 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging Hit paper breakdown → | 2014 | 1411 |
| 2 | Heart Failure: Preventing Disease and Death Worldwide Hit paper breakdown → | 2014 | 1035 |
| 3 | Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Hit paper breakdown → | 2006 | 961 |
| 4 | Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Hit paper breakdown → | 1992 | 908 |
| 5 | Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Hit paper breakdown → | 2007 | 903 |
| 6 | Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging Hit paper breakdown → | 2014 | 821 |
| 7 | Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Hit paper breakdown → | 2007 | 668 |
| 8 | Akt Activation Preserves Cardiac Function and Prevents Injury After Transient Cardiac Ischemia In Vivo Hit paper breakdown → | 2001 | 623 |
| 9 | Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking Tale Hit paper breakdown → | 2010 | 616 |
| 10 | 2005 | 535 | |
| 11 | 2001 | 381 | |
| 12 | 2000 | 345 | |
| 13 | 2010 | 345 | |
| 14 | 2010 | 329 | |
| 15 | 2008 | 313 | |
| 16 | 2011 | 305 | |
| 17 | 1998 | 293 | |
| 18 | 2004 | 288 | |
| 19 | 1994 | 244 | |
| 20 | 1995 | 204 |
About Thomas L. Force
Thomas L. Force is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging and Hematology, having authored 168 papers that have together received 21.0k indexed citations. Recurring topics across this work include Chemotherapy-induced cardiotoxicity and mitigation (23 papers), Signaling Pathways in Disease (23 papers), Cardiac Fibrosis and Remodeling (19 papers), Protein Kinase Regulation and GTPase Signaling (18 papers), Cardiac electrophysiology and arrhythmias (17 papers), Cardiovascular Function and Risk Factors (15 papers), Wnt/β-catenin signaling in development and cancer (14 papers) and Melanoma and MAPK Pathways (14 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (8.7k citations), Oncology (3.7k citations), Molecular Biology (8.8k citations), Hematology (941 citations) and Pathology and Forensic Medicine (1.3k citations). Thomas L. Force has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Joseph Vincent Bonventre, Risto Kerkelä, John M. Kyriakis, James Robert Woodgett, Richard A. Van Etten, Gerald W. Dorn, Anthony Rosenzweig, Roger Hajjar, Daniela S. Krause and Syed Haq. Their work appears in journals such as Circulation, Journal of Biological Chemistry, Circulation Research, Molecular and Cellular Biology and Journal of the American College of Cardiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.